In this article in Healthy Daily it discuses a new migraine abortive. Sounds exciting really. New research into the anatomy of a migraine has led to different angles to attack the problem.
Telcagepant is from a different class, called calcitonin gene-related peptide (CGRP) antagonists. It’s believed that brain concentrations of CGRP are elevated during a migraine. CGRP antagonists don’t seem to have blood vessel narrowing properties and, therefore, may not carry the same cardiovascular-related risks as triptans.
the pain and associated symptoms of migraine were thought to be caused by problems in brain blood vessels. But over the past 15 years, research has begun to change our understanding of the causes of migraine. New studies suggest that migraine may instead be a disorder of the nervous system. Certain small chemical messengers in the brain, including one known as calcitonin gene related peptide (CGRP), have been identified as potential mediators of migraine pain. New research is providing insight into the cause of migraine.
This new abortive med will provide some welcome relief to people who cannot take triptans, or people like me, where the breathing constriction and heart side effects are problamatic. I had thought it would take forever to get to market, but looks like it may be sooner than I thought.
“One potential benefit of the new CGRP receptor antagonist class of acute migraine treatments is the absence of vasoconstriction, a liability of the triptans, which may allow for the safe administration of telcagepant in patients with migraine with cardiovascular disease,” the study authors wrote. “However, such patients were excluded from the present study because of the contraindication for zolmitriptan, and further studies are necessary to determine the safety of telcagepant in patients with cardiovascular disease. Additional studies are also necessary to assess the long-term efficacy and safety profile of telcagepant in patients treating more than one migraine attack.” The study was published online Nov. 25 and in an upcoming print issue of The Lancet. Preliminary results from the trial were presented in June at the American Headache Society’s annual meeting, in Boston.-Healthy Daily